Abstract
Scientific objectives Endometrial hyperplasia (EH) is significant in gynecological morbidity of reproductive age women, has high risk of malignancy and associated with menstrual irregularities, dysfunctional uterine bleeding and anemia. The incidence of endometrium adenocarcinoma ranks first among genital malignancies, in recent years has tended to increase in many countries, including Ukraine. EH has tended to increase in many countries, including Ukraine, in recent years. The response to hormone therapy and prognosis of endometrial hyperplastic processes in women is largely determined by receptor status, which depends on the clinical stage and degree of histological differentiation of EH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
